Q-omics provides the consensus-scored ZDHHC20 profile across patient tissues and cancer cell-line models. ZDHHC20 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZDHHC20 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ZDHHC20 RNA expression shows 20,536 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where ZDHHC20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC20 survival associations across molecular data types. ZDHHC20 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC20 RNA expression–survival associations across cancer types. High ZDHHC20 expression shows unfavorable associations in ACC, CESC, MESO, PAAD and KIRP, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZDHHC20 RNA expression.
This table summarizes ZDHHC20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZDHHC20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC20 shows lower tumor expression in KICH and higher tumor expression in KIRC, BLCA, PAAD, BRCA and LIHC. The KIRC box plot shows higher ZDHHC20 RNA expression in tumor versus normal tissue (log2 FC = +0.671, t-test p < 0.001).
This table shows molecular features associated with ZDHHC20 in patient tissues and cancer cell lines. In patient samples, ZDHHC20 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
